Aldeyra Therapeutics' dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off. The Massachusetts-based biotech said a ...
Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for topical ocular reproxalap, a first-in-class ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback